The ASCO 2022 annual meeting was held last month, and on June 3rd, the Goldkorn Lab presented an oral abstract showcasing research done in cooperation with SWOG. Using the S1314 neo-adjuvant bladder cancer cohort, researchers from the Goldkorn Lab — led by Yi-Tsung Lu — showed that cell-free DNA methylation patterns are a biomarker to predict if patients will benefit from chemotherapy. The abstract is linked below.
Loading...
Reload document 
Open in new tab Dr. Goldkorn subsequently presented a recap of the team’s work at the “Best of SWOG at ASCO” webinar on June 29th.
